Ligand grants Sage exclusive, worldwide rights to Ligand's Captisol drug formulation technology to develop and commercialize therapeutics for CNS conditions

Ligand Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$293.7m on 10/21/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Sage Therapeutics Inc.

U.S. / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced